INDV · NASDAQ
Indivior Pharmaceuticals (INDV) Stock Price & Fundamentals
Indivior Pharmaceuticals (INDV) closed at $285.29 on Oct 9, 2026, down 0.37% from the previous close of $286.34.
Share price, past year
1Y +15.11%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $285.29 |
| Sep 30, 2026 | $297.73 |
| Aug 31, 2026 | $298.46 |
| Jul 31, 2026 | $306.83 |
| Jun 30, 2026 | $300.27 |
| May 29, 2026 | $302.34 |
| Apr 30, 2026 | $293.49 |
| Mar 31, 2026 | $282.10 |
| Feb 27, 2026 | $269.84 |
| Jan 30, 2026 | $272.14 |
| Dec 31, 2025 | $267.85 |
| Nov 28, 2025 | $256.26 |
| Oct 31, 2025 | $251.58 |
Key statistics
- Market cap
- —
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $1.33B
- Net income (TTM)
- $356.00M
- Shares outstanding
- —
- Dividend yield
- —
- 52-week range
- $243.09 – $315.28
Financials
Indivior Pharmaceuticals reported revenue of $1.24B for fiscal 2025, up 4.29% from fiscal 2024.
Indivior Pharmaceuticals earned net income of $210.00M in fiscal 2025, a net margin of 16.9%.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $1.24B | +4.3% | $210.00M | 17.0% | $1.64 | −$93.00M |
| FY2024ended Dec 31, 2024 | $1.19B | +8.7% | $7.00M | 0.6% | $0.05 | $7.00M |
| FY2023ended Dec 31, 2023 | $1.09B | +21.3% | −$126.00M | −11.5% | −$0.92 | −$308.00M |
| FY2022ended Dec 31, 2022 | $901.00M | — | −$42.00M | −4.7% | −$0.30 | −$9.00M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $343.00M | $122.00M | $0.98 |
| Q1 FY2026ended Mar 31, 2026 | $317.00M | $89.00M | $0.69 |
| Q4 FY2025ended Dec 31, 2025 | $357.00M | $103.00M | — |
| Q3 FY2025ended Sep 30, 2025 | $314.00M | $42.00M | $0.33 |
| Q2 FY2025ended Jun 30, 2025 | $302.00M | $18.00M | $0.14 |
| Q1 FY2025ended Mar 31, 2025 | $266.00M | $47.00M | $0.38 |
| Q4 FY2024ended Dec 31, 2024 | $298.00M | $21.00M | — |
| Q3 FY2024ended Sep 30, 2024 | $307.00M | $22.00M | $0.16 |
Company profile
- Name
- Indivior Pharmaceuticals, Inc.
- Ticker
- INDV
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 10710 Midlothian Turnpike, Suite 125, North Chesterfield, VA 23235
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001625297
Recent SEC filings
- Oct 6, 2026
- Sep 17, 2026
- Sep 15, 2026
- Aug 3, 2026
- Aug 3, 2026
- Aug 3, 2026
- Aug 3, 2026
- May 15, 2026
Frequently asked questions
What is Indivior Pharmaceuticals's stock price?
Indivior Pharmaceuticals (INDV) closed at $285.29 on Oct 9, 2026, down 0.37% from the previous close of $286.34.
How much revenue does Indivior Pharmaceuticals make?
Indivior Pharmaceuticals reported revenue of $1.24B for fiscal 2025, up 4.29% from fiscal 2024.
Does Indivior Pharmaceuticals pay a dividend?
Indivior Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Indivior Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures